Financial Data and Key Metrics Changes - Group normalized revenue increased by 3% to AUD 541.6 million, with normalized unpata at AUD 103.2 million, down 4.1% year-on-year [4][14][26] - Statutory net profit after tax rose by 6.4% to AUD 95.8 million, while normalized return on capital employed increased to 63.4% [6][14][26] - The cost to income ratio improved by 230 basis points in the second half compared to the first half, with a full-year ratio of approximately 58.7% [5][44][26] Business Line Data and Key Metrics Changes - Group Remuneration Services (GRS) segment saw normalized revenue slightly up to AUD 293.4 million, with novated lease sales growing by 4.1% [16][17] - Asset Management Services (AMS) revenue increased by 4.3% to AUD 185.5 million, with written down value up 6.4% [22] - Participant numbers in the Plan and Support Services (PSS) segment grew by 10.5% organically, with total customers increasing by 21.5% to over 42,600 [23][24] Market Data and Key Metrics Changes - The EV percentage of new novated sales reached 56% in Q3 before returning to around 45% in Q4, consistent with previous periods [18][19] - Demand and momentum remained strong, with order growth of 11.3% in June and July compared to the same period last year [18] - The company reported a strong customer growth across all segments, particularly in the SME segment [4][20] Company Strategy and Development Direction - The company aims to be a trusted partner providing solutions that simplify processes, focusing on customer experience, technology enablement, and broadening its ecosystem of partners [7][10] - Investments in digital solutions, AI, and automation are central to enhancing customer experience and operational productivity [8][10] - The Simply Stronger program has been completed, with expectations of improved customer experiences and productivity gains [13][29] Management's Comments on Operating Environment and Future Outlook - The company expects auto supply and used car values to remain stable, with continued growth in new client wins and NDIS participant growth supporting customer growth across all segments [33][35] - Management anticipates benefits from strategic investments and the removal of non-recurring costs in FY 2026 [35][36] - The company remains optimistic about growth opportunities despite the removal of setup fees impacting margins in the PSS segment [56][72] Other Important Information - The company executed a successful AUD 300 million private placement, enhancing investor diversity and lowering funding costs [6][21] - The Onboard Finance segment's normalization concluded in FY 2025, with expectations of neutral contributions in FY 2026 [47][52] - The company maintained a strong balance sheet with no maturities due in the next twelve months, providing flexibility for growth [31] Q&A Session Summary Question: Can you unpack the drivers for the improvement in novated yield? - The improvement was largely due to a higher proportion of plug-in hybrids at higher price points and improvements in insurance related to residual risk [39][40] Question: Is the 4.7% of novated leases through Olli incremental business? - Most of the new customers acquired through Olli are in employee brackets of 20 to 200, which was not previously targeted [41][42] Question: What should be expected for the cost to income ratio in FY 2026? - A fair assessment for FY 2026 would be around the 57% mark, with further benefits expected from productivity investments [44][46] Question: Will onboard finance be a positive contributor to NPATA for FY 2026? - It is expected to be neutral for FY 2026, with positive contributions anticipated thereafter [47][48] Question: How do you view margin within PSS with the new acquisition? - There will be a bit of downward movement on the margin in 2026, but automation and process improvements are expected to help recover margins over time [55][56] Question: What is the outlook for GRS contract renewals? - Approximately 10% of the portfolio is up for renewal over the next eighteen months, with a strong pipeline for new opportunities [86][87]

Financial Data and Key Metrics Changes - Revenue increased to $134 million, representing a 6% growth compared to the previous year [10][4] - Underlying EBITDA grew by 34% to $19.3 million, marking the strongest financial performance since the pandemic [10][11] - Underlying net profit after tax before goodwill impairment was $2.1 million, the first underlying profit since the pandemic [11][4] - Cash position improved by $2.8 million year-over-year [4] Business Line Data and Key Metrics Changes - The Skydive segment reported a revenue growth of 5% and underlying EBITDA growth of 27%, driven by improved volumes and site efficiencies [12][11] - Adventure Experiences segment saw a revenue increase of 7% and underlying EBITDA growth of 14%, with Treetops and Reef Unlimited leading the performance [15][16] - All business units reported improved earnings performance compared to previous periods [7] Market Data and Key Metrics Changes - The overall improvement in domestic and international tourism in Australia and New Zealand was a key driver for the group's performance [8][11] - The return of international visitation, particularly from the UK and Europe, was noted as a significant factor in trading performance [28] Company Strategy and Development Direction - The company will focus on four key areas: business performance improvement, sustaining trading momentum, future growth, and quality of the portfolio [23][24] - Plans for organic growth include new products and expansion of existing experiences, particularly in the marine and treetops divisions [25][26] - The company is actively looking for bolt-on acquisitions in the Outdoor Adventure and Marine segments [27] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the trading outlook due to improved operating margins and a focus on direct bookings [35][36] - The company is optimistic about the recovery of the international market, particularly from China, and expects continued growth in inbound visitation [36][40] - Management acknowledged the impact of weather on trading but remains confident in the overall business performance [71] Other Important Information - The Board declared a fully franked dividend of $0.25, the first since FY 2018, reflecting confidence in future trading momentum [4][29] - The company maintained a modest net debt and gearing level, with a closing cash balance of CAD 11.1 million [18] Q&A Session Summary Question: What is driving the company's confidence? - The confidence stems from improved operating margins, increased direct bookings, and a positive outlook for international visitation [35] Question: How does the company manage skydiving operations across different locations? - The company can transfer customers and tandem masters between locations to optimize operations based on weather conditions [38] Question: What is the rationale behind the dividend declaration? - The Board felt confident in the trading performance and outlook for FY 2026, believing the company has the capacity to pay the dividend [53] Question: What are the expectations for the Skydive segment's recovery? - The company remains confident in recovering to pre-COVID levels, despite some changes in the business structure [56] Question: How is the company managing capital expenditures? - Maintenance CapEx is driven by scheduled activities, while growth CapEx is focused on strategic investments to support future growth [60]

Financial Data and Key Metrics Changes - The company reported a significant improvement in normalized earnings before tax, which increased by 61% year on year, marking the strongest quarterly normalized EBT result in two years [5][19] - Gross margin percentage improved by 4.1 percentage points, with gross margin dollars up 13.4%, indicating effective cost management and efficiency programs [6][18] - The net loss after tax reduced by $32.5 million to $15.6 million, showing consistent improvement throughout the year [17] Business Line Data and Key Metrics Changes - The freight and fuel business experienced a turnaround, with normalized earnings loss improving by 90% year on year, moving to a positive result in Q4 FY '25 [11] - Warehousing faced ongoing challenges due to increased industry capacity and aggressive pricing tactics, leading to a need for a reset in the business [12][13] - The specialist business performed well, particularly in infrastructure projects, with a healthy pipeline for the next two years [14] Market Data and Key Metrics Changes - The trading environment in FY '25 was challenging due to ongoing economic headwinds, low business and consumer confidence, and cost of living pressures [8] - Increased competitor activity and aggressive pricing were noted, particularly in the warehousing sector, leading to a glut in capacity [9][12] - Despite these challenges, there are signs of improving sentiment among partners, indicating potential recovery [10] Company Strategy and Development Direction - The company is focused on transitioning from cost reduction to value creation as part of its Accelerate transformation program, which has one year remaining [6][22] - The New Horizons roadmap aims to establish the company as the preferred logistics provider in New Zealand by FY '28 [21] - Priorities include improving performance in warehousing, enhancing customer retention, and investing in technology for data-driven decisions [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainty in the timing and speed of economic recovery but expressed confidence in the company's positioning and readiness for growth [23][24] - The focus on gross margin improvements is expected to provide a stronger foundation for future earnings growth [24] - Management is optimistic about returning to positive normalized EBT in FY '26 [24] Other Important Information - The company has established a new funding partnership and extended its bank facility through August 2026, ensuring adequate capital for operations and growth [19][20] - A significant reduction in operating expenses of $27 million was achieved, with labor savings of approximately $15 million [17][18] Q&A Session Summary Question: Will there be any months in FY '26 with positive net profit after tax? - Management could not specify exact months but indicated a clear plan and forecast, noting that the freight and logistics sector typically ramps up after slower months [25] Question: Is a capital raise likely given the erosion of equity and uncertain net profit? - Management stated that while they expect positive EBT, they are focused on ensuring adequate capital for business operations and growth [26][27] Question: What is the EBT range guidance for the coming year? - Management refrained from providing specific guidance due to economic uncertainty but confirmed a return to positive EBT in FY '26 [28] Question: Can management provide clarity on core freight revenue and margin after the realignment of fuel services? - Management declined to share specific details on core freight results, citing confidentiality regarding customer data [29][30]

Mesoblast (MESO) H2 2025 Earnings Call August 28, 2025 06:30 PM ET Company ParticipantsSilviu Itescu - Founder, CEO & MDAndrew Chaponnel - Interim CFOMarcelo Santoro - Chief Commercial OfficerConference Call ParticipantsEdward Tenthoff - MD & Senior Research AnalystOlivia Brayer - Director & Senior Biotech AnalystElyse Shapiro - Senior Analyst - HealthcareMichael Okunewitch - Senior Research Analyst - BiotechnologyJohn Hester - Senior AnalystOperatorHello, and welcome to the Mesoblast Financial Results for ...

Financial Data and Key Metrics Changes - Revenue from cell therapy products increased to $17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil [12][15] - Net operating cash spend for the year was $50 million, consistent with the prior year, despite investments in commercial team build-out and product launch activities [13][15] - Cash on hand as of June 30 was $162 million [13] Business Line Data and Key Metrics Changes - Ryoncil generated $13.2 million in gross sales and $11.3 million in net sales after a 14.6% gross to net adjustment [12] - Cost of revenues related to product sales was $1.2 million, representing 10% of net product sales, resulting in a gross margin of 90% [15] - Selling, general, and administrative expenses rose to $39.3 million, an increase of $14.3 million from FY 2024, primarily due to the commercial team build-out and product launch [15] Market Data and Key Metrics Changes - The addressable market for Ryoncil in pediatric acute graft versus host disease (GVHD) is approximately $1 billion, with potential label extensions in adults and inflammatory bowel disease exceeding $5 billion [8] - The addressable market for chronic low back pain and heart failure with reduced ejection fraction is each over $10 billion [8] Company Strategy and Development Direction - The company aims to expand Ryoncil's label to include adult patients with GVHD and other inflammatory conditions, leveraging existing pediatric treatment centers [24][25] - Plans to initiate pivotal studies for Ryoncil in inflammatory bowel disease and chronic low back pain, targeting significant unmet medical needs [40][41] - The company is transitioning from an R&D-focused organization to a commercial biotech entity, emphasizing the importance of building a robust commercial infrastructure [87] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the successful launch of Ryoncil and the potential for continued revenue growth as more treatment centers are onboarded [76] - The company is focused on addressing the opioid crisis by providing alternatives for chronic pain management through its RexLemistroCell product [32] - Management highlighted the importance of FDA alignment for accelerated approval pathways and ongoing discussions regarding trial designs for heart failure and inflammatory bowel disease [77] Other Important Information - Ryoncil became commercially available on March 28, 2025, shortly after receiving FDA approval in December 2024 [10] - The company has onboarded 32 transplant centers in the U.S. and aims to reach 45 centers that account for 80% of pediatric bone marrow transplants [10][11] - Medicaid coverage for Ryoncil was mandated on July 1, expanding access to over 250 million lives in the U.S. [11][82] Q&A Session Summary Question: Timeline for adult GVHD label extension - Management expects to commence an adult acute GVHD trial this quarter, aiming to add Ryoncil on top of existing second-line agents [45][46] Question: Update on Phase III chronic lower back pain trial - Enrollment is progressing well with almost 40 sites, and management is optimistic about outcomes similar to previous trials [48][50] Question: Monthly treatment kits administered and inventory dynamics - Treatment kits are stocked based on weight bands, and inventory is replenished as children are treated [55][56] Question: Gross to net dynamics and adult GVHD trial design - Management expects gross to net adjustments to remain flat and will target patients on Jakafi for the adult trial [59][60] Question: Details on adult study and trial design - The trial will focus on patients with severe disease on Jakafi, aiming to increase responder rates significantly [64][65] Question: Timeline for inflammatory bowel disease trials - A KOL group is designing the trial, with updates expected this quarter [68] Question: Distribution of initial sales and revenue trajectory - It is too early to project future sales, but management expects continued strengthening of sales as infrastructure is built [73][76] Question: Market access progress - The company has engaged with over 97 payers, achieving coverage for over 250 million lives, with Medicaid coverage in place across all states [81][82]

The Gap (GAP) Q2 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsWhitney Notaro - VP & Head - IRRichard Dickson - CEO, President & DirectorKatrina O’Connell - EVP & CFOAlex Straton - MD - Equity ResearchMarni Shapiro - Managing PartnerBrooke Roach - VP - Equity ResearchLorraine Hutchinson - Managing DirectorDana Telsey - CEO & Chief Research OfficerConference Call ParticipantsMatt Boss - Equity Research AnalystIke Boruchow - MD & Senior Analyst - Retailing, Specialty Softlines & E-commerc ...

Elastic (ESTC) Q1 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsEric Prengel - Global VP - FinanceAshutosh Kulkarni - CEO & Executive DirectorNavam Welihinda - CFORaimo Lenschow - Managing DirectorSanjit Singh - Executive DirectorKash Rangan - Managing DirectorBrian Essex - Executive DirectorBrent Thill - MD & Tech Sector Leader - Software & Internet ResearchConference Call ParticipantsMatthew Hedberg - Software AnalystGeorge McGreehan - Equity Research AnalystRob Owens - MD & Senior Re ...

IREN (IREN) Q4 2025 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsMike Power - VP - IRDaniel Roberts - Co-Founder & Co-CEOBelinda Nucifora - CFOAnthony Lewis - Chief Capital OfficerKent Draper - Chief Commercial OfficerJoseph Vafi - MD - Equity ResearchCharlie Pearce - Equity Research AssociateBrett Knoblauch - Managing DirectorStephen Glagola - Director - TMT Equity ResearchBenjamin Sommers - Equity Research AssociateConference Call ParticipantsPaul Golding - US Senior Payments & Lifestyle ...

Autodesk (ADSK) Q2 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsSimon Mays-Smith - VP - IRAndrew Anagnost - President, CEO & DirectorJanesh Moorjani - EVP & CFOSaket Kalia - Managing DirectorAdam Borg - MD - Enterprise SoftwareJay Vleeschhouwer - Managing DirectorElizabeth Porter - Executive Director - Equity ResearchJoshua Tilton - DirectorSiti Panigrahi - Managing DirectorKoji Ikeda - Director - Enterprise Software Equity ResearchConference Call ParticipantsJason Celino - MD & Equity ...

Affirm (AFRM) Q4 2025 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsZane Keller - Head - IRMax Levchin - Director, Founder & CEOAdam Frisch - Senior Managing Director - EquitiesRob O’Hare - CFOWill Nance - Vice PresidentMichael Linford - COOAdib Choudhury - Senior Equity Research AssociateJohn Hecht - Managing DirectorJames Faucette - Managing DirectorReggie Smith - Executive Director - Equity ResearchHarry Bartlett - VP - Equity ResearchGiuliano Bologna - Managing DirectorConference Call Pa ...